5 Undervalued Biotechnology Stocks for Tuesday, November 05
Discover the top 5 undervalued Biotechnology stocks for Tuesday, November 05 based on AAII’s Stock Grades.Omar Beirat
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Commentary & Analysis
5 Undervalued Pharmaceuticals Stocks for Monday, September 23
Discover the top 5 undervalued Pharmaceuticals stocks for Monday, September 23 based on AAII’s Stock Grades.Eunice Kim
4 Undervalued Pharmaceuticals Stocks for Thursday, August 15
Discover the top 4 undervalued Pharmaceuticals stocks for Thursday, August 15 based on AAII’s Stock Grades.Omar Beirat
Is GT Biopharma Inc (GTBP) Stock a Good Investment?
Learn more about GT Biopharma Inc's (GTBP) stock grades for Momentum, Growth and Estimate Revisions and determine whether this Pharmaceuticals stock meets your investment needs.Jack Gilleland
Financial Summary
| Share Statistics | GTBP | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $10.6 | $252.6 | 7% |
|
| Shares Out (Mil) | 30.3 | 52.3 | 37% |
|
| Institutional Ownership | 45.9% | 92.1% | 20% |
|
| Float (Mil) | 33.5 | 40.2 | 39% |
|
| Beta | 0.64 | 0.95 | 37% |
|
| Avg Daily Volume (000s) | 485 | 455 | 58% |
|
| Price Change (52-week) |
(85.3%) | 52.9% | 5% |
|
| Growth | GTBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (0.1%) | (9.9%) | 39% |
|
| EPS (5yr) | 49.7% | 16.0% | 93 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (57.2%) | (15.6%) | 5% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | GTBP | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($30) | ($43) | 20% |
|
| EPS (TTM) | ($2.964) | ($1.600) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($13) | ($31) | 17% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 0% |
|
| Enterprise Value (Q1) (Mil) | $7 | $180 | 6% |
|
| Valuation | GTBP | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.33 | 2.56 | 34% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GTBP | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (480.7%) | (49.8%) | 0% |
|
| ROE | (921.8%) | (55.5%) | 0% |
|
| Liabilities to Assets | 24.2% | 30.3% | 16% |
|
| F-Score | 2 | 3 | 7% |
|
GT Biopharma, Inc. did not pass any screens on 7/31/2026.
